TGF-β Antagonists for Immunosuppressive Nephrotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive agents, such as cyclosporine, tacrolimus, and sirolimus, used in organ transplantation and autoimmune disease treatment, pose significant nephrotoxic side effects, including renal dysfunction and fibrosis, while their immunosuppressive activity is mediated through Transforming Growth Factor-β (TGF-β), making it challenging to reduce nephrotoxicity without compromising immunosuppressive efficacy.
Innovation Solution
Administering a low dose of a TGF-β antagonist, like an anti-TGF-β antibody, to mitigate nephrotoxic effects without substantially interfering with the immunosuppressive activity of these agents, thereby reducing TGF-β-mediated nephrotoxicity while maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If a TGF-β antagonist is administered to reduce nephrotoxicity, then renal function is improved, but immunosuppressive activity is inhibited
Solution Approach 1:
The patent applies local quality by using low doses of TGF-β antagonists that selectively target nephrotoxic pathways while preserving immunosuppressive activity. The low dose regime creates a localized effect on renal tissue fibrosis without broadly inhibiting TGF-β-mediated immunosuppression, thereby resolving the contradiction between reducing nephrotoxicity and maintaining immunosuppressive efficacy
Solution Approach 2:
The patent employs partial action by administering sub-therapeutic or low doses of TGF-β antagonists. This partial inhibition of TGF-β signaling is sufficient to reduce nephrotoxic fibrosis but insufficient to completely block immunosuppressive effects, thus achieving both goals simultaneously
2Object-affected harmful factors
If high dose TGF-β antagonist is used, then nephrotoxicity is reduced, but graft survival is compromised
Solution Approach 1:
The patent changes the dosage parameter of TGF-β antagonists from high to low doses. This parameter modification transforms the therapeutic profile, reducing nephrotoxicity protection while minimizing impact on graft survival, thereby resolving the contradiction between nephroprotection and graft longevity
3Reliability
If immunosuppressive agents are administered, then graft rejection is prevented, but nephrotoxic side effects occur
Solution Approach 1:
The patent introduces low-dose TGF-β antagonists as an intermediary agent that modulates the harmful nephrotoxic effects of immunosuppressive agents without interfering with their primary immunosuppressive function. This intermediary approach allows simultaneous use of both therapies to achieve both immunoprotection and nephroprotection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces nephrotoxicity associated with immunosuppressive agents by lowering TGF-β levels, thereby preserving graft survival and renal function without significantly impairing the immunosuppressive effects, as demonstrated in cardiac graft transplant models.
Implementation Method 1
Blocking TGF-β in non-transplant models of CsA nephrotoxicity by administration of an anti-TGF-β antibody was shown to substantially reduce overall tissue fibrosis
Data Source
AI summary
The disclosure relates to methods of ameliorating nephrotoxic side effects of immunosuppressive agents whose immunosuppressive activity is mediated via upregulation of TGF-β such as, for example, cyclosporine (CsA). The disclosure provides treatment modalities for use in patients that require immunosuppression, e.g., patients at risk of transplant rejection or having an autoimmune disease. In the methods of the invention, a TGF-β antagonist, e.g., an anti-TGF-β antibody, is administered to a patient treated with an immunosuppressive agent. Such a TGF-β antagonist is administered in a therapeutically effective amount sufficient to alleviate the nephrotoxic effects of the immunosuppressive agent without substantially interfering with immunosuppressive activity of the agent.